This is similar to the findings from other groups showing that CXCR2 inhibition using a neutralizing antibody inhibits the progression of premalignant alveolar lesions by reducing vascular density in another mouse model of lung cancer [49]. The gene discussed is CXCR2; the disease is lung carcinoma.